MX2012010720A - Proceso in vitro para la determinacion rapida de un estdo del paciente con relacion a la infeccion con micobacterium tuberculosis. - Google Patents

Proceso in vitro para la determinacion rapida de un estdo del paciente con relacion a la infeccion con micobacterium tuberculosis.

Info

Publication number
MX2012010720A
MX2012010720A MX2012010720A MX2012010720A MX2012010720A MX 2012010720 A MX2012010720 A MX 2012010720A MX 2012010720 A MX2012010720 A MX 2012010720A MX 2012010720 A MX2012010720 A MX 2012010720A MX 2012010720 A MX2012010720 A MX 2012010720A
Authority
MX
Mexico
Prior art keywords
infection
antigen
mycobacterium tuberculosis
quick determination
vitro process
Prior art date
Application number
MX2012010720A
Other languages
English (en)
Inventor
Ferdinand Hermann Bahlmann
Danilo Fliser
Martina Sester
Urban Sester
Original Assignee
Red Flag Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Flag Diagnostics Gmbh filed Critical Red Flag Diagnostics Gmbh
Publication of MX2012010720A publication Critical patent/MX2012010720A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un proceso in vitro para la determinación rápida del estado de infección de una infección de Mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de: estimular una célula T antígeno específico que está presente en una primera muestra de sangre entera con derivado de proteína purificada (PPD por sus siglas en inglés) en la presencia de anticuerpos contra CD28, o CD28 y CD49d; procesamiento de PPD por células presentadoras de antígeno (APC por sus siglas en inglés) por incubar por 1.5 horas a 2.5 horas, especialmente por 2 horas, en 35°C a 39°C, especialmente en 37°C, opcionalmente con agregar CO2 entonces agregar un inhibidor de secreción; efectuar una mezcla intensa y otra incubación por un periodo de por lo menos 2.5 horas en una temperatura de 35°C a 39°C y determinar un perfil de citosina a partir de tanto producción de IFN-? intracelular y la producción de IL-2 intracelular de la célula T antígeno específico; en donde la presencia de una tuberculosis activa se indica por un cambio del perfil de citosina hacia células positivas sencillas de IFN-? acompañadas por una disminución de células T positivas dobles IFN-y/IL-2.
MX2012010720A 2010-03-19 2011-03-21 Proceso in vitro para la determinacion rapida de un estdo del paciente con relacion a la infeccion con micobacterium tuberculosis. MX2012010720A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28270110P 2010-03-19 2010-03-19
EP10157086 2010-03-19
PCT/EP2011/054207 WO2011113953A1 (en) 2010-03-19 2011-03-21 In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis

Publications (1)

Publication Number Publication Date
MX2012010720A true MX2012010720A (es) 2013-01-29

Family

ID=42457988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010720A MX2012010720A (es) 2010-03-19 2011-03-21 Proceso in vitro para la determinacion rapida de un estdo del paciente con relacion a la infeccion con micobacterium tuberculosis.

Country Status (16)

Country Link
US (2) US20130122523A1 (es)
EP (1) EP2548019A1 (es)
JP (1) JP5925184B2 (es)
KR (1) KR20130029063A (es)
AU (1) AU2011228996B2 (es)
BR (1) BR112012023678A2 (es)
CA (1) CA2793151C (es)
CL (1) CL2012002542A1 (es)
CO (1) CO6640286A2 (es)
CU (1) CU20120141A7 (es)
MD (1) MD20120084A2 (es)
MX (1) MX2012010720A (es)
RU (1) RU2012144417A (es)
SG (1) SG184103A1 (es)
WO (1) WO2011113953A1 (es)
ZA (1) ZA201206950B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860056A1 (en) 2010-12-23 2012-06-28 Centre Hospitalier Universitaire Vaudois Methods for differentiating between disease states of mycobacterium tuberculosis infection
WO2012167307A1 (en) * 2011-06-06 2012-12-13 The University Of Melbourne Diagnosis of mycobacterial infection
US9678071B2 (en) 2012-01-12 2017-06-13 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
JP6306124B2 (ja) * 2016-11-01 2018-04-04 国立大学法人高知大学 結核検査用バイオマーカー
WO2018111536A1 (en) 2016-12-14 2018-06-21 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN107831316A (zh) * 2017-10-31 2018-03-23 扬州大学 一种用于诊断牛结核病的流式细胞术检测试剂盒
CN109777852A (zh) * 2019-01-29 2019-05-21 浙江省人民医院 特异性抗原刺激cd4淋巴细胞表达cd69用于诊断结核杆菌感染的方法
KR102326294B1 (ko) * 2019-10-27 2021-11-16 바디텍메드(주) 결핵 진단 장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
EP1833739A2 (de) * 2004-12-30 2007-09-19 Medmix Systems AG Mehrkomponenten-austragvorrichtung für flüssige und pulverförmige stoffe
BRPI0606165A2 (pt) * 2005-01-05 2009-06-02 Isis Innovation método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
EP1767937A1 (en) * 2005-09-27 2007-03-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (IRS)
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
JP5700934B2 (ja) 2007-03-16 2015-04-15 セルスティス リミテッド 細胞性免疫反応アッセイおよびそのためのキット

Also Published As

Publication number Publication date
ZA201206950B (en) 2013-05-29
BR112012023678A2 (pt) 2016-08-23
KR20130029063A (ko) 2013-03-21
CA2793151A1 (en) 2011-09-22
CO6640286A2 (es) 2013-03-22
EP2548019A1 (en) 2013-01-23
CL2012002542A1 (es) 2013-02-08
CU20120141A7 (es) 2013-01-30
MD20120084A2 (ro) 2013-04-30
AU2011228996A1 (en) 2012-10-11
RU2012144417A (ru) 2014-04-27
AU2011228996B2 (en) 2015-01-29
JP5925184B2 (ja) 2016-05-25
JP2013522637A (ja) 2013-06-13
WO2011113953A1 (en) 2011-09-22
CA2793151C (en) 2018-05-22
US20130122523A1 (en) 2013-05-16
SG184103A1 (en) 2012-10-30
US20150099652A1 (en) 2015-04-09
US9476877B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
MX2012010720A (es) Proceso in vitro para la determinacion rapida de un estdo del paciente con relacion a la infeccion con micobacterium tuberculosis.
Zhao et al. What else can CD39 tell us?
McClymont et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes
Gu et al. Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions
Pandiyan et al. Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells
Zhou et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations
Silva et al. Human naive regulatory T-cells feature high steady-state turnover and are maintained by IL-7
Komdeur et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
Bonanno et al. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
Kreutzman et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
Shu et al. Epigenetic variability of CD4+ CD25+ Tregs contributes to the pathogenesis of autoimmune diseases
Zhou et al. Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer
MY198084A (en) Expansion of non-haematopoietic tissue-resident ()()t cells and uses of these cells
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
Riva et al. Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
BRPI0710944B8 (pt) cultura biologicamente pura, e, composição e método para reduzir cólica infantil
Michalski et al. Quercetin induces an immunoregulatory phenotype in maturing human dendritic cells
Martin et al. CD40 signaling in CD8+ CD40+ T cells turns on contra-T regulatory cell functions
DiSpirito et al. Histone acetylation at the single-cell level: a marker of memory CD8+ T cell differentiation and functionality
Liang et al. Retinoic acid modulates hyperactive T cell responses and protects vitamin A–deficient mice against persistent lymphocytic Choriomeningitis virus infection
Velaga et al. Clinical-grade regulatory T cells: comparative analysis of large-scale expansion conditions
Hashizume et al. In vitro propagation and dynamics of T cells from skin biopsies by methods using interleukins-2 and-4 or anti-CD3/CD28 antibody-coated microbeads.
Xu et al. IL-15 and dendritic cells induce proliferation of CD4+ CD25+ regulatory T cells from peripheral blood
Wang et al. Gain‑of‑function of IDO in DCs inhibits T cell immunity by metabolically regulating surface molecules and cytokines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal